Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun;24(3):e70024.
doi: 10.1111/gbb.70024.

Impaired Cognitive Flexibility With Preserved Learning in an Amyloid Precursor Protein Knock-In Mouse Model of Amyloidopathy

Affiliations

Impaired Cognitive Flexibility With Preserved Learning in an Amyloid Precursor Protein Knock-In Mouse Model of Amyloidopathy

Julie R Dumont et al. Genes Brain Behav. 2025 Jun.

Abstract

Alzheimer's disease is a debilitating neurodegenerative condition characterized by amyloid beta plaques and tau neurofibrillary tangles, which leads to progressive cognitive decline. Several new mouse models of fast amyloid deposition have been generated with compound mutations, but how these affect high-level cognitive function is still not fully understood. Four cohorts of a second-generation amyloid precursor protein knock-in mouse model, AppNL-G-F/NL-G-F, which develops aggressive amyloidopathy, were compared with two different control groups that do not produce plaques (AppNL/NL and wildtype littermates), on touchscreen-based tests of learning and cognitive flexibility. AppNL-G-F/NL-G-F mice learned to discriminate between two visual stimuli during the pairwise visual discrimination (PVD) task but were impaired when the reward contingencies were reversed (the PVR task). Analyses of the correction trials indicated perseverative behavior. One cohort was further tested on the touchscreen Extinction test, which isolates the ability to withhold responding to a previously rewarded stimulus. The AppNL-G-F/NL-G-F mice extinguished their responding no differently than the AppNL/NL control group. These results indicate that compound mutations in App driving fast accumulation of plaques in this mouse model impair cognitive flexibility and may serve as a preclinical target for putative therapeutic drugs.

Keywords: APP; executive dysfunction; extinction; pairwise visual discrimination; reversal learning.

PubMed Disclaimer

Conflict of interest statement

T.J.B. and L.M.S. have established a series of targeted cognitive tests for animals, administered via touchscreen within a custom environment known as the “Bussey‐Saksida touchscreen chamber.” Cambridge Enterprise, the technology transfer office of the University of Cambridge, supported commercialization of the Bussey‐Saksida chamber, culminating in a license to Campden Instruments. Any financial compensation received from commercialization of the technology is fully invested in further touchscreen development and/or maintenance. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Female App NL‐G‐F/NL‐G‐F are impaired in reversal learning compared to both control groups. Pairwise visual discrimination learning and reversal percent correct responses, number of correction trials, and perseveration index for female mice. (A) Figure legend, cohorts, ages, and the images used during touchscreen testing. Trials to acquisition criterion, percent correct responses, correction trials, and perseveration Indices for (B–E) Cohort 1 (App NL‐G‐F/NL‐G‐F vs. App NL/NL), (F–I) Cohort 2, Timepoint 1 (App NL‐G‐F/NL‐G‐F vs. App NL‐G‐F/NL), (J–M) Cohort 2, Timepoint 2 (App NL‐G‐F/NL‐G‐F vs. App NL‐G‐F/NL). (N–Q) Cohort 3 (App NL‐G‐F/NL‐G‐F vs. Wt littermates), and (R–U) Cohort 4 (App NL‐G‐F/NL‐G‐F vs. Wt littermates). App NL‐G‐F/NL‐G‐F females required more sessions to acquire the task compared to App NL/NL controls (F). There were no significant differences in trials to acquisition in any other Cohort or timepoint. App NL‐G‐F/NL‐G‐F females were non‐significantly impaired compared with App NL/NL controls (p = 0.052) at PVR in Cohorts 1 (C) and 2 (Timepoint 1; G), with increased correction trials and perseveration in Cohort 2, Timepoint 1 (H, I). There were no significant differences between groups upon retesting at 12–13 months of age (Cohort 2, Timepoint 2; K–M). When compared with littermate controls, both Cohorts of App NL‐G‐F/NL‐G‐F female mice were impaired in reversal learning, with significant genotype effects in correct responses (O, S) and correction trials (P, T) in both Cohorts, a significant genotype effect in perseveration index in Cohort 4 (U), and a non‐significant trend toward a genotype effect in Cohort 3 (Q). Red symbols and lines depict App NL‐G‐F/NL‐G‐F groups, blue depict App NL/NL mice, yellow depict littermate wildtype controls. *p < 0.05, **p < 0.01, ***p < 0.001. Data depicted as mean ± SD (for PVD sessions to criterion) or standard error of the mean (SEM) (for baseline PVD and all PVR sessions). Cohort 1: App NL/NL n = 5, App NL‐G‐F/NL‐G‐F n = 7; Cohort 2 Timepoint 1: App NL/NL n = 15, App NL‐G‐F/NL‐G‐F n = 15; Cohort 2 Timepoint 2: App NL/NL n = 15, App NL‐G‐F/NL‐G‐F n = 10; Cohort 3: Wt littermates n = 3, App NL‐G‐F/NL‐G‐F n = 5; Cohort 4: Wt littermates n = 10, App NL‐G‐F/NL‐G‐F n = 12.
FIGURE 2
FIGURE 2
Male App NL‐G‐F/NL‐G‐F are impaired in reversal learning compared to both control groups. Pairwise visual discrimination learning and reversal percent correct responses, number of correction trials, and perseveration index for male mice. (A) Figure legend, cohorts, ages, and the images used during touchscreen testing. Trials to acquisition criterion, percent correct responses, correction trials, and perseveration indices for (B–E) Cohort 1 (App NL‐G‐F/NL‐G‐F vs. App NL‐G‐F/NL), (F–I) Cohort 2, Timepoint 1 (App NL‐G‐F/NL‐G‐F vs. App NL‐G‐F/NL), (J–M) Cohort 2, Timepoint 2 (App NL‐G‐F/NL‐G‐F vs. App NL‐G‐F/NL). (N–Q) Cohort 3 (App NL‐G‐F/NL‐G‐F vs. Wt littermates), and (R–U) Cohort 4 (App NL‐G‐F/NL‐G‐F vs. Wt littermates). There were no significant differences in trials to acquisition in any Cohort or timepoint. App NL‐G‐F/NL‐G‐F males were significantly impaired compared with App NL/NL controls at PVR in Cohorts 1 (C) and 2 (Timepoint 1; G), with increased correction trials and perseveration in Cohort 1 (D, E). There were no significant differences between groups upon retesting at 12–13 months of age (Cohort 2, Timepoint 2; K‐M). When compared with littermate controls, both Cohorts of App NL‐G‐F/NL‐G‐F mice were impaired in reversal learning (correct responses, correction trials, and perseveration index; O–Q, S–U). Red symbols and lines depict App NL‐G‐F/NL‐G‐F groups, blue depict App NL/NL mice, yellow depict littermate wildtype controls. *p < 0.05, **p < 0.01, ***p < 0.001. Data depicted as mean ± SD (for PVD sessions to criterion) or SEM (for baseline PVD and all PVR sessions). Cohort 1: App NL/NL n = 5, App NL‐G‐F/NL‐G‐F n = 11; Cohort 2 Timepoint 1: App NL/NL n = 15, App NL‐G‐F/NL‐G‐F n = 15; Cohort 2 Timepoint 2: App NL/NL n = 13, App NL‐G‐F/NL‐G‐F n = 13; Cohort 3: Wt littermates n = 9, App NL‐G‐F/NL‐G‐F n = 4; Cohort 4: Wt littermates n = 15, App NL‐G‐F/NL‐G‐F n = 9.
FIGURE 3
FIGURE 3
Male, but not female, App NL/NL controls are impaired at reversal learning compared with wildtype controls. Pairwise visual discrimination learning and reversal percent correct responses, number of correction trials, and perseveration index for the App NL/NL and wildtype controls from Cohorts 1 and 3 (younger cohorts) and Cohorts 2 (Timepoint 2) and 4 (older cohorts). (A) Genotypes, cohorts, ages, and images used during testing. There were no significant differences between the female groups at either age (B–I). However, despite acquiring the task at a similar rate (J), younger male wildtype mice were significantly impaired in percent correct responses during PVR than App NL/NL mice (K) but were no different in number of correction trials (L) or perseveration indices (M). Whereas older male mice acquired the task at a similar rate (N), App NL/NL mice made fewer correct responses (O), more correction trials (P), and had higher perseveration indices (Q) than wildtype control mice in both prior to (baseline) and following rule reversal. Note: Cohort 4 baseline trials were averaged here to conform with Cohort 2. Blue symbols and lines depict App NL/NL mice, yellow depict wildtype controls. Acquisition data depicted as mean ± SD. Baseline and reversal data depicted as mean ± SEM. *p < 0.05, **p < 0.01.
FIGURE 4
FIGURE 4
Female App NL‐G‐F/NL‐G‐F are unimpaired in extinction compared to App NL/NL controls. When compared with App NL/NL controls, App NL‐G‐F/NL‐G‐F female mice were unimpaired in extinction of a stimulus–response association. (A) Percent of responses made to the stimulus. (B) Number of touches to non‐active windows. (C) Number of touches to the response window made during the intertrial interval (ITI). (D–F) Percent responses during the first 10 trials (D), middle 10 trials (E), and last 10 trials (F) within each Session. Red symbols and line depict App NL‐G‐F/NL‐G‐F groups, blue depicts App NL/NL mice. App NL/NL n = 15, App NL‐G‐F/NL‐G‐F n = 14. Data depicted as mean ± SEM.
FIGURE 5
FIGURE 5
Male App NL‐G‐F/NL‐G‐F are unimpaired in extinction compared to App NL/NL controls. When compared with App NL/NL controls, App NL‐G‐F/NL‐G‐F male mice were unimpaired in extinction of a stimulus–response association. (A) Percent of responses made to the stimulus. (B) Number of touches to non‐active windows. (C) Number of touches to the response window made during the ITI. (D–F) Percent responses during the first 10 trials (D), middle 10 trials (E), and last 10 trials (F) within each Session. Red symbols and line depict App NL‐G‐F/NL‐G‐F groups, blue depict App NL/NL mice. App NL/NL n = 14, App NL‐G‐F/NL‐G‐F n = 15. Data depicted as mean ± SEM.

References

    1. Dementia , “World Health Organization,” 2023, https://www.who.int/news‐room/fact‐sheets/detail/dementia.
    1. Forstl H. and Kurz A., “Clinical Features of Alzheimer's Disease,” European Archives of Psychiatry and Clinical Neuroscience 249 (1999): 288–290, 10.1007/s004060050101. - DOI - PubMed
    1. McKhann G. M., Knopman D. S., Chertkow H., et al., “The Diagnosis of Dementia due to Alzheimer's Disease: Recommendations From the National Institute on Aging‐Alzheimer's Association Workgroups on Diagnostic Guidelines for Alzheimer's Disease,” Alzheimer's & Dementia 7, no. 3 (2011): 263–269, 10.1016/j.jalz.2011.03.005. - DOI - PMC - PubMed
    1. Scheltens P., Blennow K., Breteler M. M. B., et al., “Alzheimer's Disease,” Lancet 388, no. 10043 (2016): 505–517, 10.1016/S0140-6736(15)01124-1. - DOI - PubMed
    1. Woo B. K. P., Harwood D. G., Melrose R. J., et al., “Executive Deficits and Regional Brain Metabolism in Alzheimer's Disease,” International Journal of Geriatric Psychiatry 25, no. 11 (2010): 1150–1158, 10.1002/gps.2452. - DOI - PubMed

Substances